The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Community Focus Channel on VJHemOnc is an independent medical education platform, supported with funding from Johnson & Johnson (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2024 | Toxicity prevention and management when using revumenib for the treatment of AML
In this video, Eytan Stein, MD, Memorial Sloan Kettering Cancer Center, New York, NY, provides practical advice for toxicity prevention and management in patients with acute myeloid leukemia (AML) treated with revumenib. Dr Stein highlights the importance of monitoring for signs and symptoms of differentiation syndrome, assessing electrolyte levels, and performing regular electrocardiograms (EKGs) to detect possible QTc prolongation. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (AI-generated)
So at least with revumenib, which is the FDA approved drug, one of the very important things when you’re giving the drug is you have to be sure that the electrolytes are at normal levels so that the potassium is over four, magnesium over two, because you don’t want to develop complications related to this QTc prolongation. You also have to look for signs and symptoms of differentiation syndrome, weight gain, shortness of breath, renal dysfunction...
So at least with revumenib, which is the FDA approved drug, one of the very important things when you’re giving the drug is you have to be sure that the electrolytes are at normal levels so that the potassium is over four, magnesium over two, because you don’t want to develop complications related to this QTc prolongation. You also have to look for signs and symptoms of differentiation syndrome, weight gain, shortness of breath, renal dysfunction. Those are all things that you have to really worry about a little bit. So you have to monitor these patients very carefully.
For QTc prolongation, the FDA has said that you do an EKG before you start the patient on the medication. If the QTc is less than 450, you can start revumenib. Then you have to monitor EKGs weekly for the first month and then monthly thereafter. So there is some strict monitoring that needs to go on, but with the strict monitoring, we think it’s a safe drug.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
Jazz Pharmaceuticals: Consultancy, Other: consulting fees; Daiichi Sankyo, Inc.: Consultancy, Other: consulting fees; Agios Pharmaceuticals: Consultancy, Other: consulting fees; Servier: Consultancy, Other: consulting fees; Abbvie: Consultancy, Other: consulting fees; Astellas Pharmaceuticals: Consultancy, Other: consulting fees; Celgene: Consultancy, Other: consulting fees; AstraZeneca: Consultancy, Other: consulting fees; Gilead: Consultancy, Other: consulting fees; Genentech: Consultancy, Other: consulting fees.
